Add Innovative New Technology to our Market Basket. Our focus is to add innovative new tools to help address advanced cardiovascular disease, and related co-morbidities of patients being referred today to cardiovascular surgery. We are committed to growing the TMR business with the Advanced TMR Plus platform which includes two new minimally invasive handpieces for thoracoscopic and robotic assisted TMR. These new products were developed with key clinical champions to expand the TMR market. We are also committed to identifying potential new products in the cardiovascular arena

EX-10.11 3 a07285exv10w11.htm EXHIBIT 10.11 exv10w11
 

Exhibit 10.11

Amendment No. 2 to Employment Agreement
Dated September 27, 2001
Between Cardiogenesis Corporation as Company and
Michael J. Quinn as Executive

The terms and conditions of the Employment Agreement are hereby modified and amended as follows. Unless specifically defined in this Agreement, capitalized terms used herein shall have the meanings ascribed to them in the Employment Agreement.

Section 3.1, line 2, after “Three Hundred Thirty Thousand Dollars ($330,000) per annum” insert “and effective January 1, 2003, such salary shall be increased to an amount equal to Three Hundred Eighty Eight Dollars Four Hundred Twenty Seven ($388,427) per annum”.

All other terms and conditions of the Employment Agreement shall remain the same.

IN WITNESS THEREOF, the parties hereto have executed this Amendment of the latest date set forth below.

                 
COMPANY:       EXECUTIVE:
CARDIOGENESIS CORPORATION       MICHAEL J. QUINN
 
               
BY:
  Darrell Eckstein       BY:   Michael Quinn
               
 
               
NAME:
  Darrell Eckstein       NAME:   Michael Quinn
               
 
               
TITLE:
  President, CFO       TITLE:   CEO & Chairman
               
 
               
DATE:
  5/19/03       DATE:   5/19/03
               

 


 

Amendment No. 3 to Employment Agreement
Dated September 27, 2001
Between Cardiogenesis Corporation as Company and
Michael J. Quinn as Executive

The terms and conditions of the Employment Agreement are hereby modified and amended as follows. Unless specifically defined in this Agreement, capitalized terms used herein shall have the meanings ascribed to them in the Employment Agreement.

Section 3.1, line 2, after “Three Hundred Thirty Thousand Dollars ($330,000) per annum” insert “and effective January 1, 2005, such salary shall be increased to an amount equal to Four Hundred Thirty-Six Thousand Six Hundred Fifty Dollars ($436,650) per annum”.

All other terms and conditions of the Employment Agreement shall remain the same.

IN WITNESS THEREOF, the parties hereto have executed this Amendment of the latest date set forth below.

                 
COMPANY:       EXECUTIVE:
CARDIOGENESIS CORPORATION       MICHAEL J. QUINN
 
               
BY:
  Christine Ocampo       BY:   Michael J. Quinn
               
 
               
NAME:
  Christine Ocampo       NAME:   Michael J. Quinn
               
 
               
TITLE:
  VP, Chief Financial Officer       TITLE:   President and CEO
               
 
               
DATE:
  3/16/05       DATE:   3/16/05